UNLABELLED  Introduction and aim. Studies suggest that entecavir and lamivudine are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients undergoing chemotherapy or immunosuppressive therapy, but which drug is more effective is unclear. Here we meta-analyzed available evidence on relative efficacy of prophylactic entecavir or lamivudine therapy in patients with chroni...

Objective: To compare the clinical efficacy and safety of tenofovir and entecavir in chronic hepatitis B patients naïve to nucleosides and their analogues. Methods: A total of 196 patients with chronic hepatitis B, who were naïve to nucleosides and their analogues, were enrolled in this single-blinded controlled study from January 2014 to January 2015. The patients were randomly assigned to ten...

The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin <2.0 mg/dL]. Four groups of patients categorized by HBeAg status and treatment regimens were studied since May 2007. Nineteen HBeAg-positive patients (Group 1) had received entecavir ...

BACKGROUND The coexistence of HBV infection and nonalcoholic fatty liver disease (NAFLD) becomes characteristic of liver disease in China, with unknown bilateral influence. We aimed to investigate the effect of hepatic steatosis, a common hepatocyte change in NAFLD, on antiviral therapy in patients with chronic hepatitis B (CHB). METHODS AND FINDINGS We carried out a prospective nested case c...

INTRODUCTION Although most HBV infections are effectively managed by the available therapies, the treatment of the most complex cases of hepatitis B still represents an unmet medical need. Entecavir is considered a first-line therapeutic option for hepatitis B, due to its demonstrated efficacy in rapidly suppressing the viral load. Its activity is also characterized by a high genetic barrier an...

BACKGROUND/AIMS Hepatitis B core antigen is known to be a major target for virus-specific T cells and also reflects the progression of liver dissease and viral replication. Hepatitis B core antigen expression in hepatocytes leads to altered histological activity, viral replication, and immune response. The purpose of this study is to evaluate whether the topographical distribution of hepatitis ...

BACKGROUND/AIMS Entecavir is a potent and selective guanosine analogue that has demonstrated a significant antiviral efficacy against hepatitis B virus (HBV). The aim of this study was to characterize the response to entecavir and to examine the factors affecting that response. METHODS We administered 0.5 mg of entecavir once daily for more than 12 months to 114 naive chronic hepatitis B (CHB...

Entecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naïve HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4 +/- 41.5 IU/L, and at the ...

There are seven approved treatments for adults with chronic hepatitis B virus infection in the United States and European countries: interferon-α, pegylated interferon-α, lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. At present, two new analogues, entecavir and tenofovir are recommended as the first line therapy by the guidelines of European Associat...

SIRS, In the debate on the use of nucleotide/nucleoside analogues in chronic hepatitis B (CHB), recent guidelines have pointed out that drug-resistant mutations are more frequent with lamivudine, telbivudine or adefovir. For this reason, only entecavir or tenofovir is recommended as first-line monotherapy. 2 As there are no head-to-head comparisons between entecavir and tenofovir, we performed ...